Projects per year
Abstract
Here arsenohydrogels are introduced for the first time as functional, tuneable and responsive hydrogels. The distinctive redox reactivity of arsenic has been exploited to crosslink high molecular weight (Mw > 300 kDa) polymeric arsenical scaffolds (PDMAmx-co-AsAmy) via reductive coupling of As(v) to As(i) which proceeds with the formation of As-As in the form of As(i)n homocycles. Soft arsenohydrogels (G′ ∼ 400-1700 Pa) that failed in compression tests at low compression and loading are formed when the polymer weight fraction is 2.5 wt%. When the polymer weight fraction is increased to 10 wt% the mechanical properties (stiffness and relaxation) of the arsenohydrogels are significantly improved and correlate with the mole fraction of arsenic (AsAm, y) present in the copolymer scaffolds. Furthermore, increasing the mole fraction of AsAm, reduces the degree of swelling and increases the stability of the gels against hydrolysis and oxidation of the As-As crosslinks. The functionality of the polymeric arsenical scaffolds has also been exploited to load arsenohydrogels with a model organic arsenical drug. The rate and degree of release of the loaded organic arsenical under simulated oxidative stress (H2O2) is inversely proportional to the mole fraction of arsenic in the original polymer scaffold. Finally, the polymeric arsenical scaffolds and the resulting arsenohydrogels have been shown to be non-toxic to NIH/3T3 (mouse fibroblast) and PC3 (human prostate cancer) cell lines. The properties and versitility of the arsenohydrogels alludes to their potential as a functional platform for biomaterials.
| Original language | English |
|---|---|
| Pages (from-to) | 4263-4271 |
| Number of pages | 9 |
| Journal | Journal of Materials Chemistry B |
| Volume | 7 |
| Issue number | 27 |
| DOIs | |
| Publication status | Published - 1 Jan 2019 |
Projects
- 1 Finished
-
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
Davis, T. (Primary Chief Investigator (PCI)), Boyd, B. (Chief Investigator (CI)), Bunnett, N. (Chief Investigator (CI)), Porter, C. (Chief Investigator (CI)), Caruso, F. (Chief Investigator (CI)), Kent, S. (Chief Investigator (CI)), Thordarson, P. (Chief Investigator (CI)), Kearnes, M. (Chief Investigator (CI)), Gooding, J. (Chief Investigator (CI)), Kavallaris, M. (Chief Investigator (CI)), Thurecht, K. J. (Chief Investigator (CI)), Whittaker, A. K. (Chief Investigator (CI)), Parton, R. (Chief Investigator (CI)), Corrie, S. R. (Chief Investigator (CI)), Johnston, A. (Chief Investigator (CI)), McGhee, J. (Chief Investigator (CI)), Greguric, I. D. (Partner Investigator (PI)), Stevens, M. M. (Partner Investigator (PI)), Lewis, J. S. (Partner Investigator (PI)), Lee, D. S. (Partner Investigator (PI)), Alexander, C. (Partner Investigator (PI)), Dawson, K. (Partner Investigator (PI)), Hawker, C. (Partner Investigator (PI)), Haddleton, D. (Partner Investigator (PI)), Thierry, B. (Chief Investigator (CI)), Prestidge, C. A. (Chief Investigator (CI)), Meyer, A. (Project Manager), Jones-Jayasinghe, N. (Project Manager), Voelcker, N. (Chief Investigator (CI)), Nann, T. (Chief Investigator (CI)) & McLean, K. (Partner Investigator (PI))
ARC - Australian Research Council, Monash University, University of Melbourne, University of New South Wales (UNSW), University of Queensland , University of South Australia, Monash University – Internal Faculty Contribution, University of Wisconsin Madison, Memorial Sloan Kettering Cancer Center, University of California System, University College Dublin, Imperial College London, University of Warwick, Sungkyunkwan University, Australian Nuclear Science and Technology Organisation (ANSTO) , University of Nottingham
30/06/14 → 29/06/21
Project: Research